Richard Pietras to Combined Modality Therapy
This is a "connection" page, showing publications Richard Pietras has written about Combined Modality Therapy.
Connection Strength
0.151
-
Biologic basis of sequential and combination therapies for hormone-responsive breast cancer. Oncologist. 2006 Jul-Aug; 11(7):704-17.
Score: 0.065
-
Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 1999 Mar 15; 59(6):1347-55.
Score: 0.039
-
Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene. 1998 Oct 29; 17(17):2235-49.
Score: 0.038
-
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999 Apr 01; 18(13):2241-51.
Score: 0.010